--- title: "Fangzhou, Youcare Partner To Advance AI In Chronic Disease Care" type: "News" locale: "en" url: "https://longbridge.com/en/news/277337723.md" description: "Fangzhou Inc.has partnered with Youcare Pharmaceutical Group to enhance AI in chronic disease care in China. This collaboration aims to transform chronic disease services by integrating AI with Youcare's pharmaceutical expertise. The focus will be on developing digital systems for better health management in areas like cardiovascular and endocrine diseases, improving patient access to quality care and medicines. The partnership aligns with China's push for digital healthcare solutions." datetime: "2026-03-01T04:54:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277337723.md) - [en](https://longbridge.com/en/news/277337723.md) - [zh-HK](https://longbridge.com/zh-HK/news/277337723.md) generator: "portal-rs" --- # Fangzhou, Youcare Partner To Advance AI In Chronic Disease Care Add as your preferred news source on Google Add Now Fangzhou Inc. (6086.HK), a provider of AI-powered Internet healthcare solutions, announced a strategic collaboration with Youcare Pharmaceutical Group. This partnership is designed to accelerate the digital transformation of chronic disease services in China, applying artificial intelligence to improve accessibility, efficiency, and precision in patient care. Through this agreement, the two companies will jointly advance the modernization of chronic disease management by integrating digital innovation with specialized medical expertise. Their shared vision is to build a comprehensive, full-lifecycle health management ecosystem that supports patients across diverse therapeutic areas while aligning with China's national push toward digitalized and specialized healthcare. The collaboration will focus on two primary areas. First, Fangzhou and Youcare will co-develop digital systems that combine Youcare's pharmaceutical innovation and clinical knowledge with Fangzhou's AI-driven platforms. This integration aims to create an intelligent, digitally enabled chronic disease management system. The partnership will expand health management services by exploring new collaboration models in key therapeutic fields such as cardiovascular, infectious, and endocrine diseases. Leveraging AI, the companies intend to broaden patient access to high-quality medicines and professional care, ultimately strengthening the delivery of full-cycle health management solutions. For comments and feedback contact: editorial@rttnews.com Business News ### Related Stocks - [06086.HK](https://longbridge.com/en/quote/06086.HK.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [516610.CN](https://longbridge.com/en/quote/516610.CN.md) - [688658.CN](https://longbridge.com/en/quote/688658.CN.md) - [589720.CN](https://longbridge.com/en/quote/589720.CN.md) - [159929.CN](https://longbridge.com/en/quote/159929.CN.md) ## Related News & Research - [China's 1H25 Innovative Drug Out-Licensing Deal Value Exceeds USD100 Billion, Hitting New High](https://longbridge.com/en/news/293168428.md) - [CICC Initiates PA GOODDOCTOR with Outperform Rating, TP HKD14.2](https://longbridge.com/en/news/286711725.md) - [Omada Health publishes investor presentation outlining between-visit virtual care model for chronic conditions](https://longbridge.com/en/news/295141267.md) - [Investing in an age of cycles, halos and moonshots](https://longbridge.com/en/news/295511043.md) - [India’s banking regulator urges lenders to accelerate AI spend](https://longbridge.com/en/news/295499437.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**